United Therapeutics (NASDAQ:UTHR) CFO Sells $5,931,700.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $593.17, for a total transaction of $5,931,700.00. Following the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at $11,196,676.92. The trade was a 34.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

James Edgemond also recently made the following trade(s):

• On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $535.90, for a total transaction of $5,359,000.00.
• On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $564.81 on Friday. The company has a market capitalization of $24.76 billion, a PE ratio of 20.24, a price-to-earnings-growth ratio of 1.63 and a beta of 0.75. The stock has a fifty day moving average of $506.70 and a 200-day moving average of $479.24. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $607.89.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. During the same period in the previous year, the firm earned $6.19 earnings per share. United Therapeutics’s revenue for the quarter was up 7.4% compared to the same quarter last year. As a group, research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Positive Phase‑3 Tyvaso (IPF) data — the trial met its primary endpoint, supporting potential near‑term revenue upside from an expanded label and underpinning recent optimism. United Therapeutics reports positive results for lung drug
• Positive Sentiment: HC Wainwright raised price target and lifted multi‑year EPS forecasts (now Buy, $660 PT) and other brokers have moved targets higher — analyst upgrades increase buy-side conviction and support a higher valuation range. United Therapeutics Stock Price Expected to Rise, HC Wainwright Analyst Says
• Positive Sentiment: Strong earnings‑surprise history and bullish earnings outlook — coverage notes (e.g., Zacks) highlight United Therapeutics’ track record of beating estimates, increasing the probability of another upside surprise at the next report. Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Elevated options activity — traders are positioning around the clinical news and upcoming earnings, which can amplify intraday volatility but is not a direct fundamental change. United Therapeutics Target of Unusually High Options Trading
• Neutral Sentiment: Coverage/valuation pieces and peer comparisons are proliferating — these shape expectations for how Tyvaso lifts long‑term value but won’t themselves change fundamentals. (See Zacks comparison with Catalyst (CPRX) and valuation write‑ups.) CPRX or UTHR: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Insider selling by senior executives (CEO, EVP, CFO) — multi‑million dollar disposals under 10b5‑1 plans may be read as profit‑taking and can add short‑term selling pressure despite being pre‑arranged. Rothblatt SEC Filing (Example)

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rockefeller Capital Management L.P. grew its holdings in shares of United Therapeutics by 10.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,323 shares of the biotechnology company’s stock valued at $645,000 after acquiring an additional 127 shares in the last quarter. Corient Private Wealth LLC increased its stake in shares of United Therapeutics by 13.5% in the fourth quarter. Corient Private Wealth LLC now owns 19,248 shares of the biotechnology company’s stock worth $9,379,000 after acquiring an additional 2,289 shares during the last quarter. Rehmann Capital Advisory Group raised its holdings in shares of United Therapeutics by 9.8% during the fourth quarter. Rehmann Capital Advisory Group now owns 3,619 shares of the biotechnology company’s stock worth $1,767,000 after acquiring an additional 324 shares in the last quarter. Tobam boosted its position in United Therapeutics by 28.9% during the fourth quarter. Tobam now owns 9,857 shares of the biotechnology company’s stock valued at $4,803,000 after purchasing an additional 2,211 shares during the last quarter. Finally, Wick Capital Partners LLC acquired a new stake in United Therapeutics during the fourth quarter valued at $297,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on UTHR shares. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. TD Cowen raised their price objective on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a research note on Monday, March 30th. Bank of America lifted their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Wells Fargo & Company increased their target price on United Therapeutics from $486.00 to $575.00 and gave the company an “equal weight” rating in a report on Tuesday, March 31st. Finally, Royal Bank Of Canada lifted their price target on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $586.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.